Cargando…

Variation in serum urate levels in the absence of gout and urate lowering therapy

BACKGROUND: Previous studies have noted significant variation in serum urate (sUA) levels, and it is unknown how this influences the accuracy of hyperuricemia classification based on single data points. Despite this known variability, hyperuricemic patients are often used as a control group in gout...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shaffer, Andrew, Rahn, Elizabeth, Saag, Kenneth, Mudano, Amy, Gaffo, Angelo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8425059/ https://www.ncbi.nlm.nih.gov/pubmed/34493347 http://dx.doi.org/10.1186/s41927-021-00202-6

Ejemplares similares

Depressive Symptoms and the Effectiveness of a Urate‐Lowering Therapy in a Clinical Trial
por: Mrug, Sylvie, et al.
Publicado: (2020)

Serum urate, menopause, and postmenopausal hormone use: from eminence to evidence-based medicine
por: Gaffo, Angelo L, et al.
Publicado: (2008)

Adherence with urate-lowering therapies for the treatment of gout
por: Harrold, Leslie R, et al.
Publicado: (2009)

Urate‐lowering therapy for patients with gout on hemodialysis
por: Alkilany, Reem, et al.
Publicado: (2022)

Untangling the complex relationships between incident gout risk, serum urate, and its comorbidities
por: Sun, Mengying, et al.
Publicado: (2018)

Urate in fingernail represents the deposition of urate burden in gout patients
por: Chen, Haibing, et al.
Publicado: (2020)

Coevolution of URAT1 and Uricase during Primate Evolution: Implications for Serum Urate Homeostasis and Gout
por: Tan, Philip K., et al.
Publicado: (2016)

Prescription and dosing of urate-lowering therapy, rather than patient behaviours, are the key modifiable factors associated with targeting serum urate in gout
por: Dalbeth, Nicola, et al.
Publicado: (2012)

Treatment approaches and adherence to urate-lowering therapy for patients with gout
por: Aung, Thanda, et al.
Publicado: (2017)

The Effect of Decrease in Serum Urate for the Risk of Gout Flares During Urate-Lowering Therapy Initiation Among Chinese Male Gout Patients: A Prospective Cohort Study
por: Pang, Lei, et al.
Publicado: (2023)

Integrated safety studies of the urate reabsorption inhibitor lesinurad in treatment of gout
por: Terkeltaub, Robert, et al.
Publicado: (2019)

Effect of Fenofibrate in Combination with Urate Lowering Agents in Patients with Gout
por: Lee, You-Hyun, et al.
Publicado: (2006)

Urate-lowering Therapy and Chronic Kidney Disease Development in Patients with Gout
por: Yen, Fu-Shun, et al.
Publicado: (2021)

The relationship between ferritin and urate levels and risk of gout
por: Fatima, Tahzeeb, et al.
Publicado: (2018)

Association between being African-American, serum urate levels and the risk of developing hyperuricemia: findings from the Coronary Artery Risk Development in Young Adults cohort
por: Gaffo, Angelo L, et al.
Publicado: (2012)

Fluctuation and change of serum urate levels and flares in gout: results from the NOR-Gout study
por: Uhlig, T., et al.
Publicado: (2022)

Urate-lowering treatment and risk of total joint replacement in patients with gout
por: Kuo, Chang-Fu, et al.
Publicado: (2018)

Impact of diuretics on the urate lowering therapy in patients with gout: analysis of an inception cohort
por: Ranieri, Laura, et al.
Publicado: (2018)

Gout Remission as a Goal of Urate-Lowering Therapy: A Critical Review
por: Tabi-Amponsah, Adwoa Dansoa, et al.
Publicado: (2023)

Systemic Urate Deposition: An Unrecognized Complication of Gout?
por: Khanna, Puja, et al.
Publicado: (2020)

Effects of multiple genetic loci on the pathogenesis from serum urate to gout
por: Dong, Zheng, et al.
Publicado: (2017)

Decrease in Serum Urate Level Is Associated With Loss of Visceral Fat in Male Gout Patients
por: Ran, Zijing, et al.
Publicado: (2021)

Pleiotropic effect of the ABCG2 gene in gout: involvement in serum urate levels and progression from hyperuricemia to gout
por: Wrigley, Rebekah, et al.
Publicado: (2020)

The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial
por: Becker, Michael A, et al.
Publicado: (2010)

The efficacy and safety of febuxostat for urate lowering in gout patients ≥65 years of age
por: Jackson, Robert L, et al.
Publicado: (2012)

High Rate of Adherence to Urate-Lowering Treatment in Patients with Gout: Who’s to Blame?
por: Perez-Ruiz, Fernando, et al.
Publicado: (2020)

Urate-lowering therapy may mitigate the risks of hospitalized stroke and mortality in patients with gout
por: Yen, Fu-Shun, et al.
Publicado: (2020)

Interventions to improve uptake of urate-lowering therapy in patients with gout: a systematic review
por: Gill, Iqbal, et al.
Publicado: (2020)

Urate-Lowering Therapy May Prevent the Development of Coronary Artery Disease in Patients With Gout
por: Yen, Fu-Shun, et al.
Publicado: (2020)

Development of a patient decision aid for the initiation of urate-lowering therapy in gout patients
por: te Kampe, Ritch, et al.
Publicado: (2022)

Evaluation of the Relationship Between Serum Urate Levels, Clinical Manifestations of Gout, and Death From Cardiovascular Causes in Patients Receiving Febuxostat or Allopurinol in an Outcomes Trial
por: Saag, Kenneth G., et al.
Publicado: (2022)

Discovery of URAT1 SNPs and association between serum uric acid levels and URAT1
por: Cho, Sung Kweon, et al.
Publicado: (2015)

Facilitators and barriers to adherence to urate-lowering therapy in African-Americans with gout: a qualitative study
por: Singh, Jasvinder A
Publicado: (2014)

Assessing the sensitivity to change of the OMERACT ultrasound structural gout lesions during urate-lowering therapy
por: Christiansen, Sara Nysom, et al.
Publicado: (2020)

When underlying biology threatens the randomization principle — initial gout flares of urate-lowering therapy
por: Choi, Hyon K., et al.
Publicado: (2022)

Cost Comparison of Urate-Lowering Therapies in Patients with Gout and Moderate-to-Severe Chronic Kidney Disease
por: Mitri, Ghaith, et al.
Publicado: (2016)

Quality of care in gout: a clinical audit on treating to the target with urate lowering therapy in real-world gout patients
por: Janssen, Carly A., et al.
Publicado: (2017)

Physiology of Hyperuricemia and Urate-Lowering Treatments
por: Benn, Caroline L., et al.
Publicado: (2018)

Association of Specific Comorbidities with Monosodium Urate Crystal Deposition in Urate-Lowering Therapy-Naive Gout Patients: A Cross-Sectional Dual-Energy Computed Tomography Study
por: Pascart, Tristan, et al.
Publicado: (2020)

Clinical Image: In vivo urate spherulites in a patient with gout
por: Pirker, Ian, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_h74bqg1403k2k9jknoqia701a8